CAL-101 , ≥99% , 870281-82-6
CAS NO.:870281-82-6
Empirical Formula: C22H18FN7O
Molecular Weight: 415.42
MDL number: MFCD19443647
EINECS: 807-438-9
| Pack Size | Price | Stock | Quantity |
| 10MG | RMB143.20 | In Stock |
|
| 50MG | RMB219.20 | In Stock |
|
| 100MG | RMB463.20 | In Stock |
|
| 250MG | RMB736.00 | In Stock |
|
| 500MG | RMB3140.80 | In Stock |
|
| others | Enquire |
PRODUCT Properties
| Melting point: | 250-252oC |
| Boiling point: | 733.4±70.0 °C(Predicted) |
| Density | 1.47 |
| storage temp. | -20°C |
| solubility | Soluble in DMSO (>25 mg/ml) |
| form | White solid. |
| pka | 10.00±0.10(Predicted) |
| color | White |
| Stability: | Stable for 1 year from date of purchase as supplied. Solutions in DMSO may be stored at -20°C for up to 2 months. |
| InChIKey | IFSDAJWBUCMOAH-HNNXBMFYSA-N |
| SMILES | N1C2=C(C(F)=CC=C2)C(=O)N(C2=CC=CC=C2)C=1[C@@H](NC1=C2C(=NC=N1)NC=N2)CC |
Description and Uses
Idelalisib (CAS 870281-82-6) is a potent (IC50 = 2.5nM) and selective (IC50’s: PI3Ka = 820nM, PI3Kb = 565nM, PI3Kg = 89nM) PI3Kd inhibitor.1,2 Useful clinical agent for the treatment of various blood cancers. Idelalisib attenuates regulatory T cells (Treg) but not conventional T cells (Tconv) resulting in a significant increase in tumor-infiltrating antigen-specific CD8 T cells in a murine lung cancer model.3 Conversely, systemic PI3Kd inactivation antagonized anti-CTLA-4 and anti-PD-L1 treatment.4 Others have found that Idelalisib minimally influenced rituximab- and obinutuzumab-mediated Ab-dependent cellular cytotoxicity in human lymphoma cells.5
CAL-101 is a PI3K/mTOR pathway inhibitor used in the treatment of myeloid leukemia through sensitizing the cells to combatting drugs. Potent PI3K-p110-delta inhibitor.
Safety
| Symbol(GHS) | ![]() GHS08 |
| Signal word | Danger |
| Hazard statements | H372 |
| Precautionary statements | P260-P264-P270-P314-P501 |
| Safety Statements | V |
| HS Code | 29399990 |
| Hazardous Substances Data | 870281-82-6(Hazardous Substances Data) |







